Sophie Dorothea Fosså

• Ardeshirrouhanifard, Shirin; Fosså, Sophie Dorothea; Huddart, Robert; Monahan, Patrick O.; Fung, Chunkit & Song, Yiqing [Show all 16 contributors for this article] (2022). Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear and Hearing. ISSN 0196-0202. 43(3), p. 794–807. doi: 10.1097/AUD.0000000000001172.
• Monsen, Kari Vatne; Fosså, Sophie Dorothea; Myklebust, Tor Åge; Smeland, Sigbjørn; Dahl, Alv A & Stensvold, Andreas (2022). Long-term satisfaction with curative treatment and follow-up in prostate cancer survivors. Acta Oncologica. ISSN 0284-186X. 61(3), p. 357–362. doi: 10.1080/0284186X.2021.2006775.
• Van Der Perk, M. E. Madeleine; Broer, Linda; Yasui, Yutaka; Robison, Leslie L.; Hudson, Melissa M. & Laven, Joop S.E. [Show all 43 contributors for this article] (2021). Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene approach: Results from the pancareLIFE study. Cancers. ISSN 2072-6694. 13(18). doi: 10.3390/cancers13184598.
• Fard, Shirin Ardeshir Rouhani; Dinh, Paul C.; Monahan, Patrick; Fosså, Sophie Dorothea; Huddart, Robert & Fung, Chunkit [Show all 15 contributors for this article] (2021). Use of medications for treating anxiety or depression among testicular cancer survivors: A multi-institutional study. Cancer Epidemiology, Biomarkers and Prevention. ISSN 1055-9965. 30(6), p. 1129–1138. doi: 10.1158/1055-9965.EPI-20-1762.
• van den Berg, Marleen; van Dijk, Marloes; Byrne, Julianne; Berger, Claire; Dirksen, Uta & Winther, Jeanette Falck [Show all 25 contributors for this article] (2021). Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Human Reproduction. ISSN 0268-1161. 36(6), p. 1561–1573. doi: 10.1093/humrep/deab035.
• Hopland, Ola Andreas; Fosså, Sophie Dorothea; Ottosson, Fredrik; Brennhovd, Bjørn; Svindland, Aud & Hole, Knut Håkon [Show all 10 contributors for this article] (2021). Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience. Scandinavian Journal of Urology. ISSN 2168-1805. 55(4). doi: 10.1080/21681805.2021.1946135. Full text in Research Archive
• Jakobsen, Jarle; Veierød, Marit Bragelien; Grimsrud, Tom Kristian; Fosså, Sophie Dorothea; Hammarström, Bato & Kjærheim, Kristina (2021). Early detection of prostate cancer in firefighters: a register-based study of prognostic factors and survival. Occupational and Environmental Medicine. ISSN 1351-0711. doi: 10.1136/oemed-2021-107622. Full text in Research Archive
• Hellesnes, Ragnhild; Myklebust, Tor Åge; Fosså, Sophie Dorothea; Bremnes, Roy M.; Karlsdottir, Åsa & Kvammen, Øivind [Show all 10 contributors for this article] (2021). Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort. Journal of Clinical Oncology. ISSN 0732-183X. 39(32), p. 3561–3573. doi: 10.1200/JCO.21.00637. Full text in Research Archive Show summary

  PURPOSE Using complete information regarding testicular cancer (TC) treatment burden, this study aimed to investigate cause-specific non-TC mortality with impact on previous treatment with platinum-based chemotherapy (PBCT) or radiotherapy (RT). METHODS Overall, 5,707 men identified by the Cancer Registry of Norway diagnosed with TC from 1980 to 2009 were included in this population-based cohort study. By linking data with the Norwegian Cause of Death Registry, standardized mortality ratios (SMRs), absolute excess risks (AERs; [(observed number of deaths − expected number of deaths)/person-years of observation] ×10,000), and adjusted hazard ratios (HRs) were calculated. RESULTS Median follow-up was 18.7 years, during which non-TC death was registered for 665 (12%) men. Overall excess non-TC mortality was 23% (SMR, 1.23; 95% CI, 1.14 to 1.33; AER, 11.14) compared with the general population, with increased risks after PBCT (SMR, 1.23; 95% CI, 1.07 to 1.43; AER, 7.68) and RT (SMR, 1.28; 95% CI, 1.15 to 1.43; AER, 19.55). The highest non-TC mortality was observed in those < 20 years at TC diagnosis (SMR, 2.27; 95% CI, 1.32 to 3.90; AER, 14.42). The most important cause of death was non-TC second cancer with an overall SMR of 1.53 (95% CI, 1.35 to 1.73; AER, 7.94), with increased risks after PBCT and RT. Overall noncancer mortality was increased by 15% (SMR, 1.15; 95% CI, 1.04 to 1.27; AER, 4.71). Excess suicides appeared after PBCT (SMR, 1.65; 95% CI, 1.01 to 2.69; AER, 1.39). Compared with surgery, increased non-TC mortality appeared after 3 (HR, 1.47; 95% CI, 0.91 to 2.39), 4 (HR, 1.41; 95% CI, 1.01 to 1.99), and more than four (HR, 2.04; 95% CI, 1.25 to 3.35) cisplatin-based chemotherapy cycles after > 10 years of follow-up. CONCLUSION TC treatment with PBCT or RT is associated with a significant excess risk of non-TC mortality, and increased risks emerged after more than two cisplatin-based chemotherapy cycles after > 10 years of follow-up.

• Dahl, Alv A; Kiserud, Cecilie E.; Fosså, Sophie Dorothea; Loge, Jon Håvard; Reinertsen, Kristin Valborg & Ruud, Ellen [Show all 7 contributors for this article] (2021). A controlled study of major depressive episodes in long‐term childhood, adolescence, and young adult cancer survivors (The nor‐cayacs study). Cancers. ISSN 2072-6694. 13:5800(22), p. 1–13. doi: 10.3390/cancers13225800. Full text in Research Archive
• Aas, Kirsti; Berge, Viktor; Myklebust, Tor Åge & Fosså, Sophie Dorothea (2021). Comparative survival outcomes of high-risk prostate cancer ttreated with radical prostatectomy or definitive radiotherapy regimens. European Urology Open Science. ISSN 2666-1691. 26, p. 55–63. doi: 10.1016/j.euros.2021.01.011. Full text in Research Archive
• Storås, Anne Marie Holck; Fosså, Sophie Dorothea; Ursin, Giske & Kulle, Bettina (2021). Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer and Prostatic Diseases. ISSN 1365-7852. p. 1–6. doi: 10.1038/s41391-021-00445-x.
• Nome, Ragnhild V.; Småstuen, Milada Cvancarova; Fosså, Sophie D.; Kiserud, Cecilie E.; Åsvold, Bjørn Olav & Bjøro, Trine (2021). Thyroid hypofunction in aging testicular cancer survivors. Acta Oncologica. ISSN 0284-186X. p. 1–8. doi: 10.1080/0284186X.2021.1958004. Full text in Research Archive
• van der Kooi, Anne-Lotte; van Dijk, Marloes; Broer, Linda; van den Berg, Marleen; Laven, Joop S.E. & van Leeuwen, Flora [Show all 44 contributors for this article] (2021). Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. Human Reproduction. ISSN 0268-1161. 36(4), p. 1120–1133. doi: 10.1093/humrep/deaa342. Show summary

  Abstract STUDY QUESTION Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n = 465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS To evaluate ovarian function, anti-Müllerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE Meta-analysis across the three independent cohorts showed a significant interaction effect (P = 3.0 × 10−4) between rs11668344 of BRSK1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score ≥8000 mg/m2), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS Further research, validating our findings and identifying additional risk-contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by the PanCareLIFE project that has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. In addition, the DCOG-LATER VEVO study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622) and by the Children Cancer Free Foundation (Project no. 20) and the St Jude Lifetime cohort study by NCI U01 CA195547. The authors declare no competing interests.

• Thorsen, Lene; Bøhn, Synne-Kristin H.; Lie, Hanne C.; Fosså, Sophie Dorothea & Kiserud, Cecilie E. (2021). Needs for information about lifestyle and rehabilitation in long-term young adult cancer survivors. Supportive Care in Cancer. ISSN 0941-4355. 30, p. 521–533. doi: 10.1007/s00520-021-06418-z. Full text in Research Archive Show summary

  Background Healthy lifestyle and rehabilitation may mitigate late effects after cancer treatment, but knowledge about lifestyle and rehabilitation information needs among long-term young adult cancer survivors (YACSs) (≥ 5 years from diagnosis) is limited. The present study aimed to examine such information needs among long-term YACSs, and identify characteristics of those with needs. Material and methods The Cancer Registry of Norway identified long-term YACSs diagnosed with breast cancer, colorectal cancer, non-Hodgkin lymphoma, leukemia, or malignant melanoma at the age of 19–39 years, between 1985 and 2009. Survivors were mailed a questionnaire, in which respondents reported their information needs on physical activity, diet, and rehabilitation services 5–30 years post-diagnosis. Descriptive statistics and logistic regression analyses were used to examine the prevalence of information needs and associated factors. Results Of 1488 respondents (a response rate of 42%), 947 were included. Median age at diagnosis was 35 years (range 19–39) and median observation time since diagnosis was 14 years (range 5–30). In total, 41% reported information needs for information about physical activity, 45% about diet, and 47% about rehabilitation services. Information needs were associated with higher treatment intensity, increasing number of late effects, and an unhealthy lifestyle. Conclusion A large proportion of long-term YACSs report information needs regarding lifestyle and/or rehabilitation more than a decade beyond treatment. Assessments of such information needs should become a part of long-term care of these cancer survivors.

• Skalleberg, Jakob Rasmussen; Myhrum, M.; Småstuen, M.C.; Osnes, Terje; Fosså, Sophie Dorothea & Bunne, M. (2021). Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity? Acta Oncologica. ISSN 0284-186X. 60(4), p. 426–433. doi: 10.1080/0284186X.2021.1887514.
• Bjerring, Anders W.; Fosså, Sophie Dorothea; Haugnes, Hege Sagstuen; Nome, Ragnhild Veline; Stokke, Thomas Muri & Haugaa, Kristina [Show all 9 contributors for this article] (2021). The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: A 30-year follow-up. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. 22(4), p. 443–450. doi: 10.1093/ehjci/jeaa289. Full text in Research Archive
• Blindheim, Augun; Fosså, Sophie Dorothea; Babigumira, Ronnie & Andreassen, Bettina Kulle (2021). The use of reTURB in T1 bladder cancer: a Norwegian population-based study. Scandinavian Journal of Urology. ISSN 2168-1805. 55(4), p. 268–274. doi: 10.1080/21681805.2021.1917652. Full text in Research Archive
• Hellesnes, Ragnhild; Myklebust, Tor Åge; Bremnes, Roy M.; Karlsdottir, Åsa; Kvammen, Øivind & Negaard, Helene Francisca Stigter [Show all 10 contributors for this article] (2021). Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. Journal of Clinical Oncology. ISSN 0732-183X. 39(4), p. 308–318. doi: 10.1200/JCO.20.02713. Full text in Research Archive
• Dahl, Alv A; Fosså, Sophie Dorothea; Brennhovd, Bjørn & Axcrona, Karol (2020). The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. International Urology and Nephrology. ISSN 0301-1623. doi: 10.1007/s11255-020-02688-4.
• Milano, Michael T.; Dinh, Paul C.; Yang, Hongmei; Zaid, Mohammad Abu; Fosså, Sophie Dorothea & Feldman, Darren R. [Show all 9 contributors for this article] (2020). Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors. JNCI Cancer Spectrum. ISSN 2515-5091. 4(3). doi: 10.1093/JNCICS/PKAA017.
• Kerns, Sarah L.; Fung, Chunkit; Fosså, Sophie Dorothea; Dinh, Paul C.; Monahan, Patrick & Sesso, Howard D. [Show all 17 contributors for this article] (2020). Relationship of cisplatin-related adverse health outcomes with disability and unemployment among testicular cancer survivors. JNCI Cancer Spectrum. ISSN 2515-5091. 4(4), p. 1–13. doi: 10.1093/jncics/pkaa022. Show summary

  Abstract Background Few data exist on the relationship of cisplatin-related adverse health outcomes (AHOs) with disability, unemployment, and self-reported health (SRH) among testicular cancer survivors (TCS). Methods A total of 1815 TCS at least 1 year postchemotherapy underwent clinical examination and completed questionnaires. Treatment data were abstracted from medical records. A cumulative burden of morbidity score (CBMPt) encompassed the number and severity of platinum-related AHOs (peripheral sensory neuropathy [PSN], hearing loss, tinnitus, renal disease). Multivariable regression assessed the association of AHOs and CBMPt with employment status and SRH, adjusting for sociodemographic and clinical characteristics. Unemployment was compared with a male normative population of similar age, race, and ethnicity. Results Almost 1 in 10 TCS was out of work (2.4%, disability leave; 6.8%, unemployed) at a median age of 37 years (median follow-up = 4 years). PSN (odds ratio [OR] = 2.89, 95% confidence interval [CI] = 1.01 to 8.26, grade 3 vs 0, P = .048), renal dysfunction defined by estimated glomerular filtration rate (OR = 12.1, 95% CI = 2.06 to 70.8, grade 2 vs 0, P = .01), pain (OR = 10.6, 95% CI = 4.40 to 25.40, grade 2 or 3 vs 0, P < .001), and CBMPt (OR = 1.46, 95% CI = 1.03 to 2.08, P = .03) were associated with disability leave; pain strongly correlated with PSN (r2 = 0.40, P < .001). Statistically significantly higher percentages of TCS were unemployed vs population norms (age-adjusted OR = 2.67, 95% CI = 2.49 to 3.02, P < .001). PSN (OR = 2.44, 95% CI = 1.28 to 4.62, grade 3 vs 0, P = .006), patient-reported hearing loss (OR = 1.82, 95% CI = 1.04 to 3.17, grade 2 or 3 vs 0, P = .04), and pain (OR = 3.75, 95% CI = 2.06 to 6.81, grade 2 or 3 vs 0, P < .001) were associated with unemployment. Increasing severity of most cisplatin-related AHOs and pain were associated with statistically significantly worse SRH. Conclusions Our findings have important implications regarding treatment-associated productivity losses and socioeconomic costs in this young population. Survivorship care strategies should include inquiries about disability and unemployment status, with efforts made to assist affected TCS in returning to the workforce.

• Dahl, Alv A; Bentzen, Anne Gry; Fosså, Sophie Dorothea; Hess, Siri Lothe; Steen, Rita & Vistad, Ingvild [Show all 7 contributors for this article] (2020). Sexual inactivity during the last 4 weeks in long-term cervical cancer survivors: Prevalence and associated factors. Journal of Sexual Medicine. ISSN 1743-6095. 17(7), p. 1359–1369. doi: 10.1016/j.jsxm.2020.03.010. Full text in Research Archive
• Dahl, Alv A; Bentzen, Anne Gry; Fosså, Sophie Dorothea; Hess, Siri Lothe; Steen, Rita & Kiserud, Cecilie E. (2020). Long-term cervical cancer survivors on disability pension: a subgroup in need of attention from health care providers. Journal of cancer survivorship. ISSN 1932-2259. 14(4), p. 578–585. doi: 10.1007/s11764-020-00877-9. Full text in Research Archive
• Bøhn, Synne-Kristin Hoffart; Lie, Hanne Cathrine; Reinertsen, Kristin Valborg; Fosså, Sophie Dorothea; Haugnes, Hege Sagstuen & Kiserud, Cecilie E. [Show all 9 contributors for this article] (2020). Lifestyle among long-term survivors of cancers in young adulthood. Supportive Care in Cancer. ISSN 0941-4355. 29(1), p. 289–300. doi: 10.1007/s00520-020-05445-6. Full text in Research Archive
• Gullestad, Hans Petter; Haugen, Gro S. & Fosså, Sophie Dorothea (2020). Late arm and shoulder problems after axillary therapeutic lymph node dissection in patients with melanoma. Journal of Plastic Surgery and Hand Surgery. ISSN 2000-656X. doi: 10.1080/2000656X.2020.1842746.
• Skalleberg, Jakob Rasmussen; Småstuen, Milada Cvancarova; Oldenburg, Jan; Osnes, Terje; Fosså, Sophie Dorothea & Bunne, Bodil Iris Marie (2020). The relationship between cisplatin-related and age-related hearing loss during an extended follow-up. The Laryngoscope. ISSN 0023-852X. 130(9), p. E515–E521. doi: 10.1002/lary.28543.
• Fosså, Sophie Dorothea; Dahl, Alv A; Myklebust, Tor Åge; Kiserud, Cecilie E.; Nome, Ragnhild Veline & Klepp, Olbjørn [Show all 8 contributors for this article] (2020). Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study. Cancer Epidemiology. ISSN 1877-7821. 67:101774, p. 1–7. doi: 10.1016/j.canep.2020.101744.
• Stewart, Robert; Fosså, Sophie Dorothea; Hotopf, Matthew & Mykletun, Arnstein (2020). Extent of disease at first cancer presentation and previous anxiety and depressive symptoms: The HUNT study. British Journal of Psychiatry. ISSN 0007-1250. 217(2), p. 427–433. doi: 10.1192/bjp.2019.211.
• Vatne, Kari; Fosså, Sophie Dorothea; Dahl, Alv A; Myklebust, Tor Åge; Smeland, Sigbjørn & Stensvold, Andreas (2020). Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life. Scandinavian Journal of Urology. ISSN 2168-1805. p. 1–8. doi: 10.1080/21681805.2020.1854343. Full text in Research Archive
• Fosså, Sophie Dorothea; Aas, Kirsti; Muller, Christoph Rainer; Jerm, Marianne Brenn; Tandstad, Torgrim & Lilleby, Wolfgang [Show all 10 contributors for this article] (2020). Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival. Radiotherapy and Oncology. ISSN 0167-8140. 155, p. 33–41. doi: 10.1016/j.radonc.2020.10.022.
• Thorsen, Lene; Haugnes, Hege Sagstuen; Fosså, Sophie Dorothea; Brydøy, Marianne; Tandstad, Torgrim & Wisløff, Torbjørn [Show all 13 contributors for this article] (2020). Thromboembolic events after high-intensity training duringcisplatin-based chemotherapy for testicular cancer: Casereports and review of the literature. International Journal of Cancer. ISSN 0020-7136. 147(11), p. 3189–3198. doi: 10.1002/ijc.33151. Full text in Research Archive Show summary

  The randomized “Testicular cancer and Aerobic and Strength Training trial” (TAST‐trial) aimed to evaluate the effect of high‐intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin‐based chemotherapy (CBCT) for testicular cancer (TC). Here, we report on an unexpected high number of thromboembolic (TE) events among patients randomized to the intervention arm, and on a review of the literature on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were randomized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling session. The exercise intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was prematurely discontinued after inclusion of 19 of the planned 94 patients, with nine patients randomized to the intervention arm and 10 to the control arm. Three patients in the intervention arm developed TE complications; two with pulmonary embolism and one with myocardial infarction. All three patients had clinical stage IIA TC. No TE complications were observed among patients in the control arm. Our observations indicate that high‐intensity aerobic training during CBCT might increase the risk of TE events in TC patients, leading to premature closure of the TAST‐trial.

• Mellblom, Anneli; Kiserud, Cecilie E.; Rueegg, Corina Silvia; Ruud, Ellen; Loge, Jon Håvard & Fosså, Sophie Dorothea [Show all 7 contributors for this article] (2020). Self-reported late effects and long-term follow-up care among 1889 long-term Norwegian Childhood, Adolescent, and Young Adult Cancer Survivors (the NOR-CAYACS study). Supportive Care in Cancer. ISSN 0941-4355. p. 1–11. doi: 10.1007/s00520-020-05790-6. Full text in Research Archive
• Nome, Ragnhild Veline; Småstuen, Milada Cvancarova; Bjøro, Trine; Kiserud, Cecilie E. & Fosså, Sophie Dorothea (2020). Longitudinal kidney function outcome in aging testicular cancer survivors. Acta Oncologica. ISSN 0284-186X. 59:4, p. 467–474. doi: 10.1080/0284186X.2020.1724328. Full text in Research Archive
• Aas, Kirsti; Fosså, Sophie Dorothea; Myklebust, Tor Åge; Møller, Bjørn; Kvåle, Rune & Vlatkovic, Ljiljana [Show all 7 contributors for this article] (2020). Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. Cancer Medicine. ISSN 2045-7634. 9(18), p. 6646–6657. doi: 10.1002/cam4.3297. Full text in Research Archive
• Dybvik, Eva Hansen; Furnes, Ove; Havelin, Leif Ivar; Fosså, Sophie Dorothea; Trovik, Clement & Lie, Stein Atle (2020). A prospective study on cancer risk after total hip replacements for 41,402 patients linked to the Cancer registry of Norway. BMC Musculoskeletal Disorders. ISSN 1471-2474. 21, p. 1–8. doi: 10.1186/s12891-020-03605-7. Full text in Research Archive
• Blindheim, Augun Jodis; Fosså, Sophie Dorothea; Babigumira, Ronnie; Myklebust, Tor Åge; Haug, Erik Skaaheim & Arum, Carl-Jørgen [Show all 7 contributors for this article] (2020). T1 bladder cancer in Norway: treatment and survival. Scandinavian Journal of Urology. ISSN 2168-1805. 54(5), p. 370–375. doi: 10.1080/21681805.2020.1803401. Full text in Research Archive
• Dahl, Alv A; Brennhovd, Bjørn; Fosså, Sophie Dorothea & Axcrona, Karol (2020). A cross-sectional study of current work ability after radical prostatectomy. BMC Urology. ISSN 1471-2490. 20(1), p. 1–7. doi: 10.1186/s12894-020-0579-9. Full text in Research Archive
• Ryalen, Pål Christie; Stensrud, Mats Julius; Fosså, Sophie Dorothea & Røysland, Kjetil (2020). Causal inference in continuous time: an example on prostate cancer therapy. Biostatistics. ISSN 1465-4644. 21(1), p. 172–185. doi: 10.1093/biostatistics/kxy036. Full text in Research Archive
• Trendowski, Matthew R.; El-Charif, Omar; El Charif, Omar; Ratain, Mark J.; Monahan, Patrick & Mu, Zepeng [Show all 22 contributors for this article] (2019). Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy. Clinical Cancer Research. ISSN 1078-0432. 25(19), p. 5913–5924. doi: 10.1158/1078-0432.CCR-19-0113.
• El Charif, Omar; Mapes, Brandon; Trendowski, Matthew R.; Wheeler, Heather E.; Wing, Claudia & Dinh, Paul C. [Show all 23 contributors for this article] (2019). Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clinical Cancer Research. ISSN 1078-0432. 25(13), p. 4104–4116. doi: 10.1158/1078-0432.CCR-18-3179.
• Zaid, Mohammad Abu; Dinh, Paul C.; Monahan, Patrick O.; Fung, Chunkit; El-Charif, Omar & Feldman, Darren R [Show all 20 contributors for this article] (2019). Adverse health outcomes in relationship to hypogonadism after chemotherapy: A multicenter study of testicular cancer survivors. The Journal of the National Comprehensive Cancer Network. ISSN 1540-1405. 17(5), p. 459–468. doi: 10.6004/jnccn.2018.7109.
• Aksnessæther, Bjørg Yksnøy; Myklebust, Tor Åge; Solberg, Arne; Klepp, Olbjørn; Skovlund, Eva & Hoff, Solveig Roth [Show all 9 contributors for this article] (2019). Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial. International Journal of Radiation Oncology, Biology, Physics. ISSN 0360-3016. 106(4), p. 706–714. doi: 10.1016/j.ijrobp.2019.11.027. Full text in Research Archive
• Storås, Anne Marie Holck; Sanda, Martin G.; Garin, Olatz; Chang, Peter; Patil, Dattatraya & Crociani, Catrina [Show all 10 contributors for this article] (2019). A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian Journal of Urology (AJU). ISSN 2214-3882. p. 1–9. doi: 10.1016/j.ajur.2019.08.001. Full text in Research Archive
• Fung, Chunkit; Dinh, Paul C.; Fosså, Sophie Dorothea & Travis, Lois B. (2019). Testicular cancer survivorship. The Journal of the National Comprehensive Cancer Network. ISSN 1540-1405. 17(12), p. 1557–1568. doi: 10.6004/jnccn.2019.7369.
• Kvammen, Øivind; Myklebust, Tor Åge; Solberg, Arne; Møller, Bjørn; Klepp, Olbjørn & Fosså, Sophie Dorothea [Show all 7 contributors for this article] (2019). Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: A population-based prospective cohort study. PLOS ONE. ISSN 1932-6203. 14:e0225942(12), p. 1–15. doi: 10.1371/journal.pone.0225942. Full text in Research Archive
• Fosså, Sophie Dorothea; Beyer, Bud; Dahl, Alv A; Aas, Kirsti; Eri, Lars Magne & Kvan, Espen [Show all 10 contributors for this article] (2019). Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique. Scandinavian Journal of Urology. ISSN 2168-1805. p. 1–7. doi: 10.1080/21681805.2019.1693625. Full text in Research Archive
• Bucher-Johannessen, Cecilie; Page, Christian Magnus; Haugen, Trine B.; Wojewodzic, Marcin; Fosså, Sophie Dorothea & Grotmol, Tom [Show all 8 contributors for this article] (2019). Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome. Clinical Epigenetics. ISSN 1868-7075. 11:179, p. 1–13. doi: 10.1186/s13148-019-0764-4. Full text in Research Archive
• Kvåle, Rune; Myklebust, Tor Åge; Fosså, Sophie Dorothea; Aas, Kirsti; Ekanger, Christian & Helle, Svein Inge [Show all 8 contributors for this article] (2019). Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer‐specific mortality. A population‐based study of 13 198 patients. The Prostate. ISSN 0270-4137. 79(16), p. 1852–1860. doi: 10.1002/pros.23911. Full text in Research Archive Show summary

  Background: The results of studies evaluating the impact of positive surgical margins on prostate cancer‐specific mortality have been inconsistent. We, therefore, evaluated the impact of surgical margin status on subsequent secondary treatment, palliative radiotherapy, and prostate cancer‐specific mortality. Methods A total of 14 837 men treated with radical prostatectomy (RP) during the period 2001 to 2015 were identified from the Cancer Registry of Norway. Of those, 13 198 (89%) patients had complete data on the preoperative prostate‐specific antigen level, pathological T‐category, Gleason score in the prostatectomy specimen, and margin status. Multivariable Cox proportional hazards models were used to evaluate the risk, and flexible parametric models for the cumulative incidence were fitted to predict the probabilities of secondary treatment (salvage radiotherapy or prophylactic breast radiation), palliative radiotherapy, and prostate cancer‐specific mortality. Results After a median follow‐up time of 5.2 years (3591 patients with ≥8 years of follow‐up), positive surgical margins (PSMs) were independently predictive of secondary treatment (hazard ratio [HR] = 2.43, 95% confidence interval [CI] = 2.21‐2.66) and palliative radiotherapy (HR = 1.45, 95% CI = 1.03‐2.05). After 10 years, the absolute increased risk for palliative radiotherapy in patients with PSMs after RP varied between 0.1% in pT2 tumors with a Gleason score of 6, to 12% for pT3b tumors with a Gleason score of 9 to 10. PSMs were not independently associated with prostate cancer‐specific mortality (HR = 1.14, 95% CI = 0.82‐1.59). Conclusion PSMs were associated with increased application of secondary treatment and palliative radiotherapy but were not predictive of prostate cancer‐specific mortality. As the use of palliative radiotherapy was only marginally increased in patients with PSMs and the lowest‐risk disease characteristics, avoiding PSMs may be of greatest prognostic relevance in patients with higher‐risk disease characteristics.

• Hellesnes, Ragnhild; Kvammen, Øivind; Myklebust, Tor Åge; Bremnes, Roy M.; Karlsdottir, Åsa & Negaard, Helene Francisca Stigter [Show all 10 contributors for this article] (2019). Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. International Journal of Cancer. ISSN 0020-7136. 147(1), p. 21–32. doi: 10.1002/ijc.32704. Full text in Research Archive
• Lie, Hanne Cathrine; Rueegg, Corina Silvia; Fosså, Sophie Dorothea; Loge, Jon Håvard; Ruud, Ellen & Kiserud, Cecilie E. (2019). Limited evidence of non-response bias despite modest response rate in a nationwide survey of long-term cancer survivors?results from the NOR-CAYACS study. Journal of cancer survivorship. ISSN 1932-2259. 13(3), p. 353–363. doi: 10.1007/s11764-019-00757-x. Full text in Research Archive
• Dahl, Alv A; Fosså, Sophie Dorothea; Lie, Hanne Cathrine; Loge, Jon Håvard; Reinertsen, Kristin Valborg & Ruud, Ellen [Show all 7 contributors for this article] (2019). Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors. Journal of Adolescent and Young Adult Oncology. ISSN 2156-5333. 8(3), p. 304–311. doi: 10.1089/jayao.2018.0109. Full text in Research Archive
• Gjerset, Gunhild Maria; Kiserud, Cecilie E.; Loge, Jon Håvard; Fosså, Sophie Dorothea; Wisløff, Torbjørn & Gudbergsson, Sævar Berg [Show all 8 contributors for this article] (2019). Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors. Acta Oncologica. ISSN 0284-186X. 58(5), p. 682–689. doi: 10.1080/0284186X.2018.1562210. Full text in Research Archive
• Solheim, Olesya; Skalleberg, Jakob Rasmussen; Warncke, Torhild; Ørstavik, Kristin; Tropé, Claes Gøran & Fosså, Sophie Dorothea (2019). Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 98(2), p. 240–249. doi: 10.1111/aogs.13477. Full text in Research Archive Show summary

  Introduction The aim was to evaluate “overall neuropathy”, defined as peripheral paresthesia and Raynaud's phenomenon, in long‐term survivors of malignant ovarian germ cell tumors (MOGCTs) treated with cisplatin‐based chemotherapy (CBCT). Material and methods Ninety‐three MOGCT survivors recorded in Norway in 1980‐2009 (median follow up: 15 years) were included in this analysis. Forty‐nine received CBCT (CBCT group) and 44 received other or no chemotherapy (non‐CBCT group). Applying the scale for chemotherapy‐induced neurotoxicity, the prevalence of overall neuropathy (ie score >1 on a 0‐3 scale) was compared between the two groups. Forty women from the CBCT group also underwent neurophysiological and neurological examinations; results from the neurological examination were graded according to the National Cancer Institute‐Common Terminology Criteria for Adverse Effects version 4 (NCI‐CTCAE scale v4). These women were then categorized into subgroups of low (≤3 cycles of CBCT, n = 23) and high CBCT (≥4 cycles of CBCT, n = 17). Results Twenty‐eight (57%) women from the CBCT group reported overall neuropathy, compared with 20 (45%) in the non‐CBCT group (P = .06). Of the 40 MOGCT survivors in the CBCT group who underwent neurophysiological and neurological examinations, 14 (35%) showed NCI‐CTCAE grade ≥1 signs or symptoms of peripheral neuropathy. Pathological findings of NCI‐CTCAE grade 2 or 3 signs or symptoms were found in four survivors (10%) from the high CBCT subgroup, all of whom also showed objective signs of neuropathy. Conclusions Though about half of our MOGCT survivors reported overall neuropathy after CBCT, more severe pathological neurological/neurophysiological findings that impacted daily living were recorded in only 10% of them. Our observations of a similar prevalence of self‐reported overall neuropathy in the CBCT and non‐CBCT group, combined with limited objective neurological findings, warrant further study to increase the understanding of the specific pathophysiological pathways of long‐term CBCT‐induced neuropathy.

• Bøhn, Synne-Kristin Hoffart; Thorsen, Lene; Kiserud, Cecilie E.; Fosså, Sophie Dorothea; Lie, Hanne Cathrine & Loge, Jon Håvard [Show all 9 contributors for this article] (2019). Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood. Acta Oncologica. ISSN 0284-186X. 58(5), p. 753–762. doi: 10.1080/0284186X.2018.1557344.
• van den Berg, Marleen; van Dijk, Marloes; Byrne, Julianne; Campbell, Helen; Berger, Claire & Borgmann-Staudt, Anja [Show all 26 contributors for this article] (2018). Fertility among female survivors of childhood, adolescent, and young adult cancer: Protocol for two pan-European studies (PanCareLIFE). Journal of Medical Internet Research. ISSN 1438-8871. 20:e10824(9), p. 1–13. doi: 10.2196/10824.
• Kerns, Sarah L.; Fung, Chunkit; Monahan, Patrick O.; Ardeshir-Rouhani-Fard, Shirin; Abu Zaid, Mohammad I. & Williams, Annalynn M. [Show all 20 contributors for this article] (2018). Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: A multi-institutional study. Journal of Clinical Oncology. ISSN 0732-183X. 36(15), p. 1505–1512. doi: 10.1200/JCO.2017.77.0735.
• van der Kooi, Anne-Lotte; Clemens, Eva; Broer, Linda; Zolk, Oliver; Byrne, Julianne & Campbell, Helen [Show all 26 contributors for this article] (2018). Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer. ISSN 1471-2407. 18(1). doi: 10.1186/s12885-018-4834-3.
• Zaid, Mohammad Abu; Gathirua-Mwangi, Wambui G; Fung, Chunkit; Monahan, Patrick O.; El-Charif, Omar & Williams, Annalynn M [Show all 18 contributors for this article] (2018). Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. The Journal of the National Comprehensive Cancer Network. ISSN 1540-1405. 16(3), p. 257–265. doi: 10.6004/jnccn.2017.7046.
• Feldman, Darren R.; Ardeshir-Rouhani-Fard, Shirin; Monahan, Patrick O.; Sesso, Howard D.; Fung, Chunkit & Williams, Annalynn M. [Show all 16 contributors for this article] (2018). Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: Application of the Framingham Risk Score. Clinical Genitourinary Cancer. ISSN 1558-7673. 16(4), p. e761–e769. doi: 10.1016/j.clgc.2018.01.011.
• Byrne, Julianne; Grabow, Desiree; Campbell, Helen; O'Brien, Kylie; Bielack, Stefan & am Zehnhoff-Dinnesen, Antoinette [Show all 63 contributors for this article] (2018). PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European Journal of Cancer. ISSN 0959-8049. 103, p. 227–237. doi: 10.1016/j.ejca.2018.08.007.
• Hjelle, Line Veronika; Gundersen, Per Ole Mobråten; Hellesnes, Ragnhild; Sprauten, Mette; Brydøy, Marianne & Tanstad, Torgrim [Show all 11 contributors for this article] (2018). Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors. Acta Oncologica. ISSN 0284-186X. 57(10), p. 1392–1400. doi: 10.1080/0284186X.2018.1473641.
• Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C & Cathomas, R [Show all 36 contributors for this article] (2018). ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up. Annals of Oncology. ISSN 0923-7534. 29(8), p. 1658–1686. doi: 10.1093/annonc/mdy217.
• Aas, Kirsti; Fosså, Sophie Dorothea; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge & Vlatkovic, Ljiljana [Show all 8 contributors for this article] (2018). Is time from diagnosis to radical prostatectomy associated with oncological outcomes? . World Journal of Urology. ISSN 0724-4983. 37(8), p. 1571–1580. doi: 10.1007/s00345-018-2570-6.
• Wedde, Trude Baastad; Småstuen, Milada Cvancarova; Brabrand, Sigmund; Fosså, Sophie Dorothea; Kaasa, Stein & Tafjord, Gunnar [Show all 9 contributors for this article] (2018). Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. Radiotherapy and Oncology. ISSN 0167-8140. p. 1–7. doi: 10.1016/j.radonc.2018.10.013. Full text in Research Archive
• Fosså, Sophie Dorothea; Fung, Chunkit & Dahl, Alv A (2018). Late adverse outcomes after treatment of testicular cancer. Der Onkologe. ISSN 0947-8965. 24(10), p. 802–808. doi: 10.1007/s00761-018-0462-4.
• Fung, Chunkit; Dinh, Paul; Ardeshir-Rouhani-Fard, Shirin; Schaffer, Kerry; Fosså, Sophie Dorothea & Travis, Lois B. (2018). Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Advances in Urology. ISSN 1687-6369. 2018:8671832, p. 1–20. doi: 10.1155/2018/8671832.
• Bøhn, Synne-Kristin Hoffart; Fosså, Sophie Dorothea; Wisløff, Torbjørn & Thorsen, Lene (2018). Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer. ISSN 0941-4355. 27(3), p. 1001–1011. doi: 10.1007/s00520-018-4389-5.
• Haugnes, Hege Sagstuen; Stenklev, Niels Christian; Brydøy, Marianne; Dahl, Olav; Wilsgaard, Tom & Laukli, Einar [Show all 7 contributors for this article] (2018). Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncologica. ISSN 0284-186X. 57(8), p. 1075–1083. doi: 10.1080/0284186X.2018.1433323.
• Ávila, Mónica; Patel, Laila; López, Silvia; Cortés-Sanabria, Laura; Garin, Olatz & Pont, Àngels [Show all 14 contributors for this article] (2018). Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. ISSN 0305-7372. 66, p. 23–44. doi: 10.1016/j.ctrv.2018.03.005.
• Parker, Christopher C.; Coleman, Robert Edward; Sartor, Oliver; Vogelzang, Nicholas J.; Bottomley, David & Heinrich, Daniel [Show all 29 contributors for this article] (2018). Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology. ISSN 0302-2838. 73(3), p. 353–360. doi: 10.1016/j.eururo.2017.06.021.
• Chen, Haitao; Ewing, Charles M; Zheng, Sigun; Grindedal, Eli Marie; Cooney, Kathleen A. & Wiley, Kathleen E. [Show all 14 contributors for this article] (2018). Genetic factors influencing prostate cancer risk in Norwegian men. The Prostate. ISSN 0270-4137. 78(3), p. 186–192. doi: 10.1002/pros.23453. Full text in Research Archive
• Nome, Ragnhild Veline; Bjøro, Trine; Paus, Elisabeth; Bjerner, Johan; Fosså, Sophie Dorothea & Steen, Rita [Show all 8 contributors for this article] (2017). Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors. Clinical Biochemistry. ISSN 0009-9120. 52, p. 73–79. doi: 10.1016/j.clinbiochem.2017.11.016.
• Dolan, M. Eileen; El Charif, Omar; Wheeler, Heather E.; Gamazon, Eric R.; Ardeshir-Rouhani-Fard, Shirin & Monahan, Patrick [Show all 19 contributors for this article] (2017). Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clinical Cancer Research. ISSN 1078-0432. 23(19), p. 5757–5768. doi: 10.1158/1078-0432.CCR-16-3224.
• Van Leeuwen, Marieke; Kieffer, Jacobien M; Efficace, Fabio; Fosså, Sophie Dorothea; Bolla, Michel & Collette, Laurence [Show all 21 contributors for this article] (2017). International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. Health and Quality of Life Outcomes. ISSN 1477-7525. 15(1). doi: 10.1186/s12955-017-0670-4.
• Fung, Chunkit; Sesso, Howard D.; Williams, Annalynn M.; Kerns, Sarah L.; Monahan, Patrick & Zaid, Mohammad Abu [Show all 18 contributors for this article] (2017). Multi-institutional assessment of adverse health outcomes among north American testicular cancer survivors after modern cisplatin-based chemotherapy. Journal of Clinical Oncology. ISSN 0732-183X. 35(11), p. 1211–1222. doi: 10.1200/JCO.2016.70.3108.
• Johannsdottir, Inga Marie; Hamre, Hanne Mari; Fosså, Sophie Dorothea; Loge, Jon Håvard; Drolsum, Liv & Lund, May-Brith [Show all 8 contributors for this article] (2017). Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors. Journal of Adolescent and Young Adult Oncology. ISSN 2156-5333. 6(3), p. 470–476. doi: 10.1089/jayao.2017.0018.
• Wheeler, Heather E.; Gamazon, Eric R.; Frisina, Robert D.; Perez-Cervantes, Carlos; Charif, Omar El & Mapes, Brandon [Show all 21 contributors for this article] (2017). Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clinical Cancer Research. ISSN 1078-0432. 23(13), p. 3325–3333. doi: 10.1158/1078-0432.CCR-16-2809.
• Holm, Henriette Veiby; Dahl, Alv A; Klepp, Olbjørn & Fosså, Sophie Dorothea (2017). Moderne behandling av prostatakreft med fjernmetastaser. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 137(11), p. 803–805. doi: 10.4045/tidsskr.16.0265.
• Aas, Kirsti; Axcrona, Karol; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge & Axcrona, Ulrika [Show all 8 contributors for this article] (2017). Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Urology. ISSN 0090-4295. 110, p. 140–147. doi: 10.1016/j.urology.2017.07.048.
• Axcrona, Karol; Nilsson, Rasmus; Brennhovd, Bjørn; Sørebø, Øystein; Fosså, Sophie Dorothea & Dahl, Alv A (2017). Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations. BMC Urology. ISSN 1471-2490. 17(1). doi: 10.1186/s12894-017-0302-7. Full text in Research Archive Show summary

  Background Recently, the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26) was recommended for the assessment of adverse effects after the treatment of prostate cancer without clear reasons. This decision encouraged us to review the questionnaire development from the UCLA Prostate Cancer Index (UCLA-PCI) to the EPIC-16 CP with a focus on psychometric properties. We also reviewed PubMed for papers concerning such properties of the EPIC-26 since 2012 (latest review in 2011). Finally, we examined the psychometric properties of the EPIC-26 in a sample of Norwegian males treated with robot-assisted laparoscopic prostatectomy (RALP). Methods This study used three methods: (1) Comparison of the content of the UCLA-PCI, EPIC-50, EPIC-26, and EPIC-16 CP; (2) Review of EPIC-26 and EPIC-16 CP papers in PubMed from 2012 to 2016, identifying papers reporting on the psychometric properties of these questionnaires; and (3) Psychometric examination of the EPIC-26 rating in 651 Norwegian men treated with RALP at a mean of 3.2 years post-surgery. Results The questionnaire development showed a significant increase in bother versus function items, and the EPIC-26 contains eight function and 18 bother items. Twelve papers concerning the EPIC-26 available on PubMed since 2012 support the psychometric properties of the EPIC-26. The Norwegian EPIC-26 findings supported the psychometric properties of the EPIC-26, but suggested six subdomains both by exploratory and confirmatory factor analyses. Conclusions In general our examinations supported the adequate psychometric properties of the EPIC-26, although the factor structure, construct and predictive validity of the instrument should be examined further.

• Vatne, Kari; Stensvold, Andreas; Myklebust, Tor Åge; Møller, Bjørn; Svindland, Aud & Kvåle, Rune [Show all 7 contributors for this article] (2017). Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncologica. ISSN 0284-186X. 56(10), p. 1295–1301. doi: 10.1080/0284186X.2017.1314006.
• Jacobsen, Ellisiv Lærum; Bye, Asta; Aass, Nina Kathrine; Fosså, Sophie Dorothea; Grotmol, Kjersti Støen & Kaasa, Stein [Show all 9 contributors for this article] (2017). Norwegian reference values for the Short-Form Health Survey 36: development over time. Quality of Life Research. ISSN 0962-9343. p. 1–12. doi: 10.1007/s11136-017-1684-4. Full text in Research Archive
• Lie, Hanne Cathrine; Mellblom, Anneli; Brekke, Mette; Finset, Arnstein; Fosså, Sophie Dorothea & Kiserud, Cecilie E. [Show all 8 contributors for this article] (2017). Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma. Supportive Care in Cancer. ISSN 0941-4355. 25(8), p. 2445–2454. doi: 10.1007/s00520-017-3651-6.
• Skalleberg, Jakob Rasmussen; Popova, Olesya; Fosså, Sophie Dorothea; Småstuen, Milada C; Osnes, Terje & Gundersen, Per Ole Mobråten [Show all 7 contributors for this article] (2017). Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Gynecologic Oncology. ISSN 0090-8258. 145(1), p. 148–153. doi: 10.1016/j.ygyno.2017.02.006.
• Thorsen, Lene; Kirkegaard, Camilla; Loge, Jon Håvard; Kiserud, Cecilie E.; Johansen, Merethe Lia & Gjerset, Gunhild Maria [Show all 10 contributors for this article] (2017). Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer. BMC Research Notes. ISSN 1756-0500. 10(214). doi: 10.1186/s13104-017-2531-y. Full text in Research Archive
• Gilbert, Ethel S.; Curtis, Rochelle E.; Hauptmann, Michael; Kleinerman, Ruth A.; Lynch, Charles F. & Stovall, Marilyn [Show all 28 contributors for this article] (2017). Stomach cancer following Hodgkin lymphoma, testicular cancer and cervical cancer: a pooled analysis of three international studies with a focus on radiation effects. Radiation Research. ISSN 0033-7587. 187(2), p. 186–195. doi: 10.1667/RR14453.1.
• Grov, Ellen Karine; Fosså, Sophie Dorothea & Dahl, Alv A (2017). A controlled study of the influence of comorbidity on activities of daily living in elderly cancer survivors (the HUNT-3 survey). Journal of Geriatric Oncology. ISSN 1879-4068. 8(5), p. 328–335. doi: 10.1016/j.jgo.2017.05.007. Show summary

  Objectives: To examine the influence of somatic comorbidity on Activity of Daily Living (ADL) problems in cancer survivors ≥70 years (ECSs) based on data from The Health Study of Nord-Trøndelag County (HUNT-3) 2006–08. Material andMethods: Among participants of the HUNT-3 survey, 599 ECSs had a diagnosis of one invasive cancer according to both The Cancer Registry of Norway and self-report. Three controls without cancer aged ≥70 years for each ECS were drawn from the HUNT-3 sample.We compared personal-ADL (P-ADL) and instrumental-ADL (I-ADL) problems for ECSs and differences between ADL problems for ECSs with and without comorbidity and controls with and without comorbidity. Results: The prevalence of P-ADL problems was 3.5% among ECSs and 2.9% among controls (p = 0.97) and for I-ADL 28.5% versus 21.4% (p = 0.01), respectively. In bivariate analyses where ECSs versus controls was the dependent variable, presence of I-ADL problems, higher age, being female, paired relationship, poor self-rated health, hospitalization last year, and low level of neuroticism were associated being ECSs. In multivariate analyses, these variables, except I-ADL-problems and paired relationship, remained significantly associated being ECSs. No significant differenceswere shown for P-ADL problemswhen comparing ECSs and controlswith comorbidity, and ECSswith andwithout comorbidity. ECSswith comorbidity reported significantlymore I-ADL-problems than controls with comorbidity, and ECSswith comorbidity had significantly more I-ADL-problems than ECSs without comorbidity. Conclusion: Our results reflect common factors found in ADL studies in the elderly population. Health personnel have to be particularly observant on I-ADL problems among female ECSs, and those reporting poor self-rated health or comorbidity.

• Selland, Mette; Smeland, Knut Bjøro; Bjøro, Trine; Falk, Ragnhild Sørum; Fosså, Sophie Dorothea & Gjesdal, Clara Gram [Show all 12 contributors for this article] (2017). Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation. Acta Oncologica. ISSN 0284-186X. 56(4), p. 590–598. doi: 10.1080/0284186X.2016.1267870.
• Gjerset, Gunhild Maria; Loge, Jon Håvard; Kiserud, Cecilie E.; Fosså, Sophie Dorothea; Gudbergsson, Sævar Berg & Oldervoll, Line Merethe [Show all 8 contributors for this article] (2017). Perceived needs for different components in a rehabilitation program among cancer survivors with chronic fatigue compared to survivors without chronic fatigue. Acta Oncologica. ISSN 0284-186X. 56(2), p. 245–253. doi: 10.1080/0284186X.2016.1266091. Full text in Research Archive
• Johannsdottir, Inga Marie; Karlstad, Øystein; Loge, Jon Håvard; Fosså, Sophie Dorothea; Kiserud, Cecilie E. & Skurtveit, Svetlana (2017). Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. Journal of Adolescent and Young Adult Oncology. ISSN 2156-5333. 6(1), p. 120–126. doi: 10.1089/jayao.2016.0041.

View all works in Cristin

• Storås, Anne Marie Holck; Kulle, Bettina & Fosså, Sophie Dorothea (2022). Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway. Acta Oncologica. ISSN 0284-186X. doi: 10.1080/0284186X.2022.2051204.
• Aksnessæther, Bjørg Yksnøy; Myklebust, Tor Åge; Solberg, Arne; Klepp, Olbjørn H; Skovlund, Eva & Hoff, Solveig Roth [Show all 9 contributors for this article] (2020). In Reply to Sari et al. International Journal of Radiation Oncology, Biology, Physics. ISSN 0360-3016. 107(2), p. 388–389. doi: 10.1016/j.ijrobp.2020.02.027.
• Agrawal, Vaibhav; Dinh, Paul C.; Fung, Chunkit; Monahan, Patrick; Althouse, Sandra & Norton, Kelli [Show all 11 contributors for this article] (2020). Adverse health outcomes among US testicular cancer survivors after cisplatin-based chemotherapy vs surgical management. JNCI Cancer Spectrum. ISSN 2515-5091. 4:pkz079(2), p. 1–9. doi: 10.1093/JNCICS/PKZ079.
• Aas, Kirsti; Fosså, Sophie Dorothea; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge & Vlatkovic, Ljiljana [Show all 8 contributors for this article] (2018). Increasing Time from Diagnosis to Radical Prostatectomy (RP-interval) is Not Associated with Adverse Oncological Outcomes: Implications for cancer patient pathways (CPPs). European Urology. Supplement. ISSN 1569-9056. 17(14), p. e2825–e2827. doi: 10.1016/S1569-9056%2818%2933709-6.
• Bucher-Johannessen, Cecilie; Page, Christian M.; Haugen, Trine B.; Fosså, Sophie Dorothea; Haugnes, Hege Sagstuen & Grotmol, Tom [Show all 7 contributors for this article] (2018). Epigenetic changes in testicular cancer survivors treated with cisplatin.
• Fosså, Sophie Dorothea (2017). Re: Behandling eller aktiv monitorering ved prostatakreft? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 137(4), p. 259–260. doi: 10.4045/tidsskr.17.0046.
• Holm, Henriette Veiby; Dahl, Alv A; Klepp, Olbjørn & Fosså, Sophie Dorothea (2017). H.V. Holm og medarbeidere svarer :. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 137(14/15). doi: 10.4045/tidsskr.17.0579.
• Torstveit, Ann Helen; Dahl, Alv A; Fosså, Sophie Dorothea & Utne, Inger (2017). Chronic Fatigue in Testicular Cancer Survivors.
• Jacobsen, Ellisiv Lærum; Bye, Asta; Aass, Nina Kathrine; Fosså, Sophie Dorothea; Grotmol, Kjersti Støen & Kaasa, Stein [Show all 9 contributors for this article] (2017). Correction to: Norwegian reference values for the Short-Form Health Survey 36: development over time. Quality of Life Research. ISSN 0962-9343. p. 1–3. doi: 10.1007/s11136-017-1708-0. Full text in Research Archive
• Fung, Chunkit; Fosså, Sophie Dorothea; Milano, Michael T.; Sahasrabudhe, Deepak M.; Peterson, Derick R. & Travis, Lois B. (2016). Reply to S. Alanee et al. Journal of Clinical Oncology. ISSN 0732-183X. 34(11), p. 1285–1286. doi: 10.1200/JCO.2015.65.7015.

View all works in Cristin